About the Company

Achaogen (NasdaqGM: AKAO) is a biotechnology Company focused on the development of novel antibiotics to address the rising rates of bacterial resistance. The Company’s lead product candidate is plazomicin, a next-generation aminoglycoside for the treatment of serious gram negative infections. Achaogen is currently conducting the EPIC Phase III study in complicated urinary tract infections (cUTI) and expects to report topline results in the first quarter of 2017. The Company is also testing plazomicin against a broad range of infections caused by carbapenem-resistant Enterobacteriaceae (CRE) in the CARE Phase III study and expects to report data from this trial in the first half of 2017.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research